Aroa Biosurgery Reports Strong Symphony Results in DFUs

Auckland, New Zealand, October 5, 2026

Symphony Demonstrates Higher Wound Closure Rates

The randomized study showed a significant difference in complete wound closure after 12 weeks. 55% of diabetic foot ulcers achieved complete wound closure among patients treated with Symphony plus standard of care, compared with 35% among patients receiving standard of care alone. The difference was statistically significant, with a reported p-value of 0.039. These findings indicate that incorporating Symphony into standard wound management was associated with a higher proportion of patients achieving complete closure during the study period. The trial also demonstrated a reduction in the average time required for wounds to achieve complete closure. Mean time to complete wound closure was 65.4 days with Symphony plus standard of care, compared with 73.2 days with standard of care alone, representing a reduction of 7.8 days. This difference was also statistically significant, with a reported p-value of 0.041. Faster wound closure is an important clinical objective in diabetic foot ulcers because prolonged open wounds can remain vulnerable to complications and can create substantial burdens for patients and healthcare providers.

Aroa’s Matrix Technology Targets Hard-to-Heal Wounds

Symphony™ is Aroa Biosurgery’s cellular, acellular and matrix-like product, or CAMP, developed to support the treatment of hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers. The technology combines AROA ECM™ with high molecular weight hyaluronic acid (HMWHA). According to the company, HMWHA has anti-inflammatory properties and can retain approximately 1,000 times its weight in water, characteristics that may be useful in the complex wound environment associated with chronic wounds. The trial evaluated patients with Wagner Grade 1 or 2 DFUs, including ulcers involving the full thickness of the skin as well as deeper wounds extending into structures such as ligaments, tendons, joint capsules or deep fascia. Participants were randomly assigned to receive either weekly Symphony plus standard of care or standard of care alone for up to 12 weeks or until complete wound closure. The multicenter design and randomized methodology provide a stronger level of evidence for evaluating the effectiveness of the wound-care technology.

Clinical Evidence Supports Symphony’s Wound-Care Potential

The results represent an important clinical milestone for Aroa Biosurgery as the company seeks to strengthen the evidence supporting Symphony in diabetic wound care. Aroa said the findings are expected to contribute to product differentiation, clinical adoption and evolving U.S. reimbursement requirements. The company also highlighted the importance of robust randomized clinical evidence as healthcare providers and payors increasingly seek data demonstrating meaningful improvements in patient outcomes. Diabetic foot ulcers remain a major challenge in wound management, particularly when wounds are difficult to heal using conventional approaches. The Symphony results add to the clinical evidence surrounding advanced wound-care technologies and their potential role alongside established standards of care.

The study’s statistically significant findings on both wound closure rates and healing time provide measurable outcomes that may be relevant to clinicians evaluating treatment options for complex diabetic wounds. Aroa Biosurgery is a New Zealand-based soft-tissue regeneration company developing and commercializing technologies for complex wound healing and soft-tissue reconstruction. The latest Symphony findings further demonstrate the company’s focus on combining biomaterial science with clinical evidence to address challenging wound-care needs.

Source: Aroa Biosurgery press release